• SCTX share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of SCTX shares has increased $0.86 since the market last closed. This is a 2.68% rise.

  • Last closed at $33.00.

Key terms

About SCTX

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $624.75M

    A market capitalization between $300 million and $2 billion places SCTX in the small capitalization category.

Key terms

Smart score

Latest SCTX news

Sep 08, 2026 6:20am ET Wall Street Analysts Are Bullish on Top NA Picks by TipRanks Sep 03, 2026 6:15am ET Kapoor Reiterates Buy on Scribe, Maintaining $60 Price Target Ahead of Key STX-1150 Clinical Milestones by TipRanks Sep 02, 2026 4:30pm ET Scribe Therapeutics reports Q2 EPS ($2.62), consensus ($3.72) by TipRanks Aug 31, 2026 9:50am ET Deere upgraded, Lumentum initiated: Wall Street’s top analyst calls by TipRanks Aug 31, 2026 6:15am ET Scribe Therapeutics initiated with a Buy at H.C. Wainwright by TipRanks Aug 20, 2026 11:00am ET Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX) by TipRanks Aug 18, 2026 1:10pm ET Leerink starts Scribe Therapeutics at Outperform on X-editor platform by TipRanks Aug 18, 2026 9:40am ET Norwegian Cruise downgrade, Duolingo upgraded: Wall Street’s top analyst calls by TipRanks Aug 18, 2026 6:10am ET Scribe Therapeutics initiated with an Outperform at Leerink by TipRanks Aug 18, 2026 5:35am ET Scribe Therapeutics initiated with a Buy at Guggenheim by TipRanks Aug 18, 2026 5:05am ET Scribe Therapeutics initiated with an Overweight at Wells Fargo by TipRanks Aug 18, 2026 4:15am ET Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs by TipRanks Jul 29, 2026 10:02pm ET Insiders Double Down as Big Money Pours Into Scribe Therapeutics by TipRanks Jul 27, 2026 5:27pm ET Scribe Therapeutics Updates Governance Following Initial Public Offering by TipRanks Jul 27, 2026 11:25am ET Opening Day: Scribe Therapeutics makes strong trading debut by TipRanks Jul 24, 2026 12:00pm ET Scribe Therapeutics opens at $25, IPO priced at $15 per share by TipRanks Jul 24, 2026 11:25am ET Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share by TipRanks Jul 24, 2026 11:00am ET Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share by TipRanks Jul 24, 2026 6:05am ET Scribe Therapeutics 8.58M share IPO priced at $15.00 by TipRanks
Sep 02, 2026 4:05pm ET Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights by GlobeNewswire Sep 01, 2026 8:00am ET Scribe Therapeutics to Participate in Upcoming Investor Conferences by GlobeNewswire Jul 27, 2026 4:05pm ET Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement by GlobeNewswire Jul 23, 2026 9:08pm ET Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering by GlobeNewswire

SCTX Financials

1-year income & revenue

  • SCTX total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • SCTX net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • SCTX earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

SCTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

SCTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    SCTX's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $624.75M

    A market capitalization between $300 million and $2 billion places SCTX in the small capitalization category.

Key terms

Latest investing news